Efficacy and safety of everolimus in de novo heart transplant recipients.
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2015
At a glance
- Drugs Ciclosporin; Everolimus; Mycophenolate mofetil
- Indications Heart transplant rejection; Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 Jul 2009 Primary endpoint 'Creatinine clearance' has not been met; results published in 'Transplantation'.
- 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History